Compare AbbVie Inc (ABBV) vs Canopy Growth Corp (CGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Canopy Growth Corp — how do they compare? AbbVie Inc trades at $259.41 (market cap $453.12B), while Canopy Growth Corp trades at $1 (market cap $446.06M). The key difference: AbbVie Inc is far larger — about 1015.8× Canopy Growth Corp's market cap, and AbbVie Inc pays a 2.7% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| ABBV | CGC | |
|---|---|---|
Market Cap | $453.12B | $446.06M |
Sector | Health | Health |
52-Week High | $265.97 | $1.92 |
52-Week Low | $197.38 | $0.86 |
Enterprise Value | $517.38B | $403.40M |
Dividend Yield | 2.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $260.12, up 1.81% today, with a bullish technical signal and strong institutional support. Recent earnings beats and robust revenue growth of 10% year-over-year in Q4 2025 highlight operational strength, driven by Skyrizi and Rinvoq offsetting Humira declines. The stock is near resistance at $262, with a consensus price target of $281.41 suggesting upside potential.
The outlook remains positive due to a diversified pipeline and dividend growth, but risks include patent expirations in the 2030s and high debt levels. Analyst consensus is strongly bullish with 71% buy ratings, though valuation metrics like a P/E of 72.44 warrant caution for growth sustainability.
CGC trades at $0.9755, down 2.4% today, with a bearish technical signal and negative earnings trends. The company reported a net loss of $598.12 million for 2025, though revenue showed sequential stabilization. Analyst consensus is mixed with 33% buy ratings, while recent news highlights potential turnaround efforts and acquisition speculation.
Outlook remains challenged by persistent losses and cash burn, but cost-cutting and European expansion offer growth potential. Key risks include high debt, regulatory uncertainty, and competitive pressures. Investors should weigh speculative upside against fundamental weaknesses in the volatile cannabis sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →
